Cardiovascular disease, hypertension
Conditions
Interventions
Valsartan 80 mg + hydrochlorothiazide 12.5mg per day for 8 weeks.
Valsartan 80 mg + cilnidipine 10mg per day for 8 weeks.
Sponsors
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with morning blood pressure level (measured by home sphygmomanometer owned by patients) of 135/85 mmHg or above. 2) Patients on using of valsartan 80 mg per day. 3) Male or female, aged 20 years old or above. Registration: 1) Patients with home morning blood pressure level of 135/85 mmHg or above for 3 days or above during provisionally registration period.
Exclusion criteria
Exclusion criteria: 1) Pregnant or possibly pregnant. 2) Patients on the use of calcium channel blocker. 3) Patients on the use of diuretics. 4) History of allergy to the study drug. 5) Patients considered as inappropriate to participate in this study by attending physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure variability from nocturnal to morning (difference of morning blood pressure and nocturnal blood pressure). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Mean value and variability of nocturnal blood pressure and morning blood pressure. 2) Difference of nocturnal blood pressure and morning blood pressure and its changes among the patients stratified by baseline nocturnal systolic blood pressure. 3) Association between temperature (room temperature measured by thermosensor embedded sphygmomanometer) and blood pressure value. 4) Comparison of the clinic blood pressure (measured in a sitting position [twice] and standing position [twice]) at baseline and at 8 weeks (final observation) between groups. | — |
Countries
Japan
Contacts
Public ContactSUNLIGHT Research support Office
SUNLIGHT Research support Office Satt Co., Ltd.
Outcome results
None listed